Abrupt onset of type 1 diabetes mellitus during recombinant interferon-alpha 2b therapy in a patient with chronic hepatitis B

World Journal of Gastroenterology

Volumn 14, Issue 29, 2008, Pages 4713-4715

  Lv, Yuan Yuan ^a   Shi, Bing Yin ^a   Guo, Hui ^a  

^a XI'AN JIAOTONG UNIVERSITY   (China)

Author keywords

Autoimmune disease; Chronic hepatitis B; Interferon alpha; Islet cell autoantibody; Type 1 diabetes mellitus

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; C PEPTIDE; GLUCOSE; HEMOGLOBIN A1C; HEPATITIS B CORE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; INSULIN; ISOPHANE INSULIN; RECOMBINANT ALPHA2B INTERFERON; VIRUS DNA; ALPHA2B INTERFERON; RECOMBINANT PROTEIN;

ADULT; ARTICLE; BEDTIME DOSAGE; CASE REPORT; CHINA; DIABETIC KETOACIDOSIS; DIET RESTRICTION; DRUG WITHDRAWAL; FEMALE; GLUCOSE BLOOD LEVEL; HEPATITIS B; HEPATITIS B VIRUS; HOSPITAL ADMISSION; HUMAN; HYPERGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; POLYDIPSIA; POLYURIA; PROTEIN SECRETION; TREATMENT DURATION; URINALYSIS; CHEMICALLY INDUCED DISORDER; RISK FACTOR;

ADULT; CHINA; DIABETES MELLITUS, TYPE 1; FEMALE; HEPATITIS B, CHRONIC; HUMANS; INTERFERON ALFA-2B; RECOMBINANT PROTEINS; RISK FACTORS;

EID: 58149204325     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.14.4713     Document Type: Article

References (15)

1. Mofredj A, Howaizi M, Grasset D, Licht H, Loison S, Devergie B, Demontis R, Cadranel JF. Diabetes mellitus during interferon therapy for chronic viral hepatitis. Dig Dis Sci 2002; 47: 1649-1654
2. Cozzolongo R, Betterle C, Fabris P, Paola Albergoni M, Lanzilotta E, Manghisi OG. Onset of type 1 diabetes mellitus during peginterferon alpha-2b plus ribavirin treatment for chronic hepatitis C. Eur J Gastroenterol Hepatol 2006; 18: 689-692
3. Radhakrishnan S, Upadhyay A, Mohan N, Dhar A, Walia HK, Zubaidi G. Late development of diabetes mellitus after interferon-alfa and ribavirin therapy for chronic hepatitis C: a case report. Med Princ Pract 2005; 14: 281-283
4. Betterle C, Fabris P, Zanchetta R, Pedini B, Tositti G, Bosi E, de Lalla F. Autoimmunity against pancreatic islets and other tissues before and after interferon-alpha therapy in patients with hepatitis C virus chronic infection. Diabetes Care 2000; 23: 1177-1181
5. Konrad T, Vicini P, Zeuzem S, Toffolo G, Briem D, Lormann J, Herrmann G, Wittmann D, Lenz T, Kusterer K, Teuber G, Cobelli C, Usadel KH. Interferon-alpha improves glucose tolerance in diabetic and non-diabetic patients with HCV-induced liver disease. Exp Clin Endocrinol Diabetes 1999; 107: 343-349
6. Konrad T, Zeuzem S, Vicini P, Toffolo G, Briem D, Lormann J, Herrmann G, Berger A, Kusterer K, Teuber G, Cobelli C, Usadel KH. Evaluation of factors controlling glucose tolerance in patients with HCV infection before and after months therapy with interferon-alpha. Eur J Clin Invest 2000; 30: 111-121
7. Tai TY, Lu JY, Chen CL, Lai MY, Chen PJ, Kao JH, Lee CZ, Lee HS, Chuang LM, Jeng YM. Interferon-alpha reduces insulin resistance and beta-cell secretion in responders among patients with chronic hepatitis B and C. J Endocrinol 2003; 178: 457-465
8. Tosone G, Borgia G, Gentile I, Cerini R, Conte MC, Orlando R, Piazza M. A case of pegylated interferon alpha-related diabetic ketoacidosis: can this complication be avoided? Acta Diabetol 2007; 44: 167-169
9. Jabr FI, Ordinario MM. Sudden onset of diabetic ketoacidosis during pegylated interferon alfa therapy. Am J Med 2003; 115: 158-159
10. Fabris P, Betterle C, Floreani A, Greggio NA, de Lazzari F, Naccarato R, Chiaramonte M. Development of type 1 diabetes mellitus during interferon alfa therapy for chronic HCV hepatitis. Lancet 1992; 340: 548
11. Piquer S, Hernandez C, Enriquez J, Ross A, Esteban JI, Genesca J, Bonifacio E, Puig-Domingo M, Simo R. Islet cell and thyroid antibody prevalence in patients with hepatitis C virus infection: effect of treatment with interferon. J Lab Clin Med 2001; 137: 38-42
12. Wesche B, Jaeckel E, Trautwein C, Wedemeyer H, Falorni A, Frank H, von zur Muhlen A, Manns MP, Brabant G. Induction of autoantibodies to the adrenal cortex and pancreatic islet cells by interferon alpha therapy for chronic hepatitis C. Gut 2001; 48: 378-383
13. Wasmuth HE, Stolte C, Geier A, Gartung C, Matern S. Induction of multiple autoantibodies to islet cell antigens during treatment with interferon alpha for chronic hepatitis C. Gut 2001; 49: 596-597
14. Soultati AS, Dourakis SP, Alexopoulou A, Deutsch M, Archimandritis AJ. Simultaneous development of diabetic ketoacidosis and Hashitoxicosis in a patient treated with pegylated interferon-alpha for chronic hepatitis C. World J Gastroenterol 2007; 13: 1292-1294
15. Fabris P, Floreani A, Tositti G, Vergani D, De Lalla F, Betterle C. Type 1 diabetes mellitus in patients with chronic hepatitis C before and after interferon therapy. Aliment Pharmacol Ther 2003; 18: 549-558